CorMedix Shares Plunge After 1H Guidance Missed Expectations

Dow Jones

03/25

By Sabela Ojea

Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter.

The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months.

The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue.

The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

March 25, 2025 11:31 ET (15:31 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2522001807"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522001807\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522001807?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 23:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522001807","market":"sg","top_or_hot":-1,"title":"CorMedix Shares Plunge After 1H Guidance Missed Expectations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter. \n</p>\n<p>\n  The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue. \n</p>\n<p>\n  The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 11:31 ET (15:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Shares Plunge After 1H Guidance Missed Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Shares Plunge After 1H Guidance Missed Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-25 23:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter. \n</p>\n<p>\n  The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue. \n</p>\n<p>\n  The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2025 11:31 ET (15:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522001807","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522001807","pubTimestamp":1742916660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter.The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months.The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue.The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CRMD":"CorMedix Inc."},"translate_title":"上半年指引未达预期后CorMedix股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of CorMedix Tuesday dropped after the company's outlook for the first half of 2025 disappointed investors despite beating expectations in the fourth quarter. \n\n\n  The stock was down 31% at $7.39 in morning trading, on pace for the largest percent decrease since Aug. 22, when it fell 57%. Shares have dropped 80% over the past 12 months. \n\n\n  The biopharmaceutical company said it expects revenue between $50 million to $60 million for the first half. Analysts polled by FactSet are forecasting revenue of $31 million for the first quarter and $32.6 million for the second quarter, equal to $63.6 million in combined revenue. \n\n\n  The company's outlook implies a deceleration in revenue for the second quarter after it guided for a first-quarter topline performance of more than $33 million. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 11:31 ET (15:31 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}